|
WO2021081217A1
|
|
Compositions for drg-specific reduction of transgene expression
|
|
WO2021080991A1
|
|
Aav3b variants with improved production yield and liver tropism
|
|
WO2021080975A1
|
|
Compositions and methods for reducing cholesterol levels
|
|
US2021115400A1
|
|
Micro-engineered models of the human eye and methods of use
|
|
WO2021077066A1
|
|
Lipid and lipid nanoparticle formulation for drug delivery
|
|
WO2021077067A1
|
|
Lipid nanoparticles and formulations thereof for car mrna delivery
|
|
WO2021072312A1
|
|
Compositions and methods for targeting cd13 and tim-3 with car t cells to treat acute myeloid leukemia
|
|
WO2021072320A1
|
|
Rapid manufacturing of absorbent substrates for soft, conformable sensors and conductors
|
|
WO2021067528A1
|
|
Compounds for the treatment of human immunodeficiency virus
|
|
US2021095036A1
|
|
Humanized Anti-GDNF family alpha-receptor 4 (GRF-alpha-4) Antibodies and Chimeric Antigen Receptors (CARs)
|
|
US2021087294A1
|
|
Monoclonal Antibody Against Canine Fibroblast Activation Protein that Cross-Reacts with Mouse and Human Fibroblast Activation Protein (FAP)
|
|
US2021087295A1
|
|
Disrupting tumor tissues by targeting fibroblast activation protein (fap)
|
|
US2021088392A1
|
|
Ultra-Sensitive, Mechanically-Responsive Optical Metasurfaces Via Strain Amplification
|
|
WO2021055892A1
|
|
Compositions and methods comprising ionizable lipid nanoparticies encapsulating barcoded mrna
|
|
US2021087470A1
|
|
Microrobots In Nematic Liquid Crystals
|
|
IL277312D0
|
|
Beta glucan and cd40 agonist combination immunotherapy
|
|
US2021069239A1
|
|
Compositions and Methods Comprising Prostate Stem Cell Antigen (PSCA) Chimeric Antigen Receptors (CARs)
|
|
US2021062273A1
|
|
Methods for rapid detection of egfr variants and amplification
|
|
WO2021011455A1
|
|
Devices and methods for rapid screening of drugs of abuse and other analytes
|
|
US2021008193A1
|
|
Protein antigens for vaccinating against nontypeable haemophilus influenzae
|
